Related Experiment Video

Updated: Dec 21, 2025

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

17.3K

GSK-3 in liver diseases: Friend or foe?

Maria R Emma1, Giuseppa Augello1, Antonella Cusimano1

  • 1Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy.

Biochimica Et Biophysica Acta. Molecular Cell Research
|May 18, 2020
PubMed

Insights

Developing new therapies for liver diseases like hepatitis and cancer is crucial. Glycogen synthase kinase 3 (GSK-3) is a promising target for novel pharmacological treatments, offering potential for improved disease management.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Pharmacology

Background:

  • Liver diseases, including viral hepatitis, NAFLD, and HCC, present significant global health challenges with limited curative options.
  • Understanding disease pathogenesis via signaling pathways is key to developing effective therapeutic strategies.
  • Pharmacological approaches targeting specific molecules in signal transduction pathways show promise for liver disease treatment.

Purpose of the Study:

  • To review the role of glycogen synthase kinase 3 (GSK-3) in the pathogenesis of various liver diseases.
  • To explore emerging drugs targeting GSK-3β for potential therapeutic applications in liver disease management.

Main Methods:

  • Literature review focusing on GSK-3's involvement in liver disease.
  • Analysis of current and emerging pharmacological agents targeting GSK-3β.
  • Discussion of the potential impact of GSK-3 targeting therapies on liver disease management.

Main Results:

  • GSK-3 is implicated in the pathogenesis of multiple liver conditions.
  • Several novel drugs targeting GSK-3β are under development.
  • Targeting GSK-3β presents a promising therapeutic avenue for liver diseases.

Conclusions:

  • GSK-3 represents a significant molecular target for the treatment of liver diseases.
  • Emerging GSK-3β inhibitors hold potential for improving the management of hepatitis, NAFLD, and HCC.
  • Further research into GSK-3 targeted therapies is warranted for liver disease intervention.
Keywords:
Glycogen synthase kinase 3 (GSK-3)Hepatitis B virus (HBV)Hepatitis C virus (HCV)Hepatocellular carcinoma (HCC)Non-alcoholic fatty liver disease (NAFLD)Signaling pathways

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.6K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.2K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
155
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.1K